79 related articles for article (PubMed ID: 8140937)
1. Use of a rat model for the simultaneous assessment of pharmacokinetic and pharmacodynamic aspects of bisphosphonate treatment: application to the study of intravenous 14C-labeled 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate.
Koopmans SJ; van der Wee-Pals L; Löwik CW; Papapoulos SE
J Bone Miner Res; 1994 Feb; 9(2):241-6. PubMed ID: 8140937
[TBL] [Abstract][Full Text] [Related]
2. Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo.
van der Pluijm G; Binderup L; Bramm E; van der Wee-Pals L; De Groot H; Binderup E; Löwik C; Papapoulos S
J Bone Miner Res; 1992 Aug; 7(8):981-6. PubMed ID: 1442212
[TBL] [Abstract][Full Text] [Related]
3. Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis.
Cremers SC; Lodder MC; Den Hartigh J; Vermeij P; Van Pelt P; Lems WF; Papapoulos SE; Dijkmans BA
J Rheumatol; 2004 Sep; 31(9):1732-7. PubMed ID: 15338492
[TBL] [Abstract][Full Text] [Related]
4. Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate.
Papapoulos SE; Hoekman K; Löwik CW; Vermeij P; Bijvoet OL
J Bone Miner Res; 1989 Oct; 4(5):775-81. PubMed ID: 2816519
[TBL] [Abstract][Full Text] [Related]
5. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.
Hornby SB; Evans GP; Hornby SL; Pataki A; Glatt M; Green JR
Calcif Tissue Int; 2003 Apr; 72(4):519-27. PubMed ID: 12574877
[TBL] [Abstract][Full Text] [Related]
6. Effects of a bisphosphonate on bone histomorphometry and dynamics in the canine cruciate deficiency model of osteoarthritis.
Myers SL; Brandt KD; Burr DB; O'Connor BL; Albrecht M
J Rheumatol; 1999 Dec; 26(12):2645-53. PubMed ID: 10606377
[TBL] [Abstract][Full Text] [Related]
7. Bilateral tibial marrow ablation in rats induces a rapid hypercalcemia arising from extratibial bone resorption inhibitable by methylprednisolone or deflazacort.
Magnuson SK; Booth R; Porter S; Gorski JP
J Bone Miner Res; 1997 Feb; 12(2):200-9. PubMed ID: 9041051
[TBL] [Abstract][Full Text] [Related]
8. Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate.
Schweitzer DH; Zwinderman AH; Vermeij P; Bijvoet OL; Papapoulos SE
J Bone Miner Res; 1993 Feb; 8(2):175-82. PubMed ID: 8442435
[TBL] [Abstract][Full Text] [Related]
9. The effect of bisphosphonate on alveolar bone resorption following mucoperiosteal flap surgery in the mandible of rats.
Yaffe A; Fine N; Alt I; Binderman I
J Periodontol; 1995 Nov; 66(11):999-1003. PubMed ID: 8558403
[TBL] [Abstract][Full Text] [Related]
10. Changes in bone volume and bone resorption by olpadronate treatment in an experimental model of uremic bone disease.
Tomat A; Gamba CA; Mandalunis P; De Grandi MC; Somoza J; Friedman S; Zeni S
J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):174-81. PubMed ID: 15951635
[TBL] [Abstract][Full Text] [Related]
11. Effects of tiludronate on bone mass, structure, and turnover at the epiphyseal, primary, and secondary spongiosa in the proximal tibia of growing rats after sciatic neurectomy.
Murakami H; Nakamura T; Tsurukami H; Abe M; Barbier A; Suzuki K
J Bone Miner Res; 1994 Sep; 9(9):1355-64. PubMed ID: 7529459
[TBL] [Abstract][Full Text] [Related]
12. Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions.
Body JJ; Magritte A; Seraj F; Sculier JP; Borkowski A
J Bone Miner Res; 1989 Dec; 4(6):923-8. PubMed ID: 2692407
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
14. Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral density.
Ammann P; Rizzoli R; Caverzasio J; Shigematsu T; Slosman D; Bonjour JP
J Bone Miner Res; 1993 Dec; 8(12):1491-8. PubMed ID: 8304051
[TBL] [Abstract][Full Text] [Related]
15. Pamidronate prevents bone loss associated with carrageenan arthritis by reducing resorptive activity but not recruitment of osteoclasts.
Moran EL; Fornasier TL; Bogoch TR
J Orthop Res; 2000 Nov; 18(6):873-81. PubMed ID: 11192246
[TBL] [Abstract][Full Text] [Related]
16. Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study.
Body JJ; Dumon JC; Piccart M; Ford J
J Bone Miner Res; 1995 Aug; 10(8):1191-6. PubMed ID: 8585422
[TBL] [Abstract][Full Text] [Related]
17. Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.
Schoenig GP; Hartnagel RE; Osimitz TG; Llanso S
Drug Metab Dispos; 1996 Feb; 24(2):156-63. PubMed ID: 8742226
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
Miller PD
Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
[TBL] [Abstract][Full Text] [Related]
19. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonate effects in rat unloaded hindlimb bone loss model: three-dimensional microcomputed tomographic, histomorphometric, and densitometric analyses.
Barou O; Lafage-Proust MH; Martel C; Thomas T; Tirode F; Laroche N; Barbier A; Alexandre C; Vico L
J Pharmacol Exp Ther; 1999 Oct; 291(1):321-8. PubMed ID: 10490920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
